Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved

Antioxidants and Redox Signaling

Volumn 25, Issue 12, 2016, Pages 685-701

  Shanmugasundaram, Karthigayan ^a   Block, Karen ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

high throughput analysis; mitochondrial electron transfer chain; NOX oxidases; oxidative stress; renal cancer; tumor heterogeneity

Indexed keywords

MICRORNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRANSCRIPTOME; ANTIOXIDANT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ALGORITHM; ANATOMICAL CONCEPTS; BIOINFORMATICS; BIRT HOGG DUBE SYNDROME; CARCINOGENESIS; CELL HETEROGENEITY; CELL PROLIFERATION; CLEAR CELL CARCINOMA; DIABETES MELLITUS; ELECTRON TRANSPORT; EPIGENETICS; HIGH THROUGHPUT SCREENING; HISTOLOGY; HUMAN; INFORMATION PROCESSING; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY COLLECTING TUBULE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; RENAL CARCINOGENESIS; REVIEW; BIOLOGY; DRUG EFFECTS; GENETICS; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SOFTWARE;

ALGORITHMS; ANTIOXIDANTS; CARCINOGENESIS; COMPUTATIONAL BIOLOGY; HUMANS; KIDNEY NEOPLASMS; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SOFTWARE;

EID: 84991627937     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6569     Document Type: Review

References (167)

1. Abente EJ, Subramanian M, Ramachandran V, and Najafi-Shoushtari SH. MicroRNAs in obesity-associated disorders. Arch Biochem Biophys 589: 108-119, 2016.
2. Aggarwal BB, Vijayalekshmi RV, and Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15: 425-430, 2009.
3. Arai E and Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 4: 58-73, 2010.
4. Bandiera S, Cartault F, Jannot AS, Hatem E, Girard M, Rifai L, Loiseau C, Munnich A, Lyonnet S, and Henrion-Caude A. Genetic variations creating microRNA target sites in the FXN 3′-UTR affect frataxin expression in Friedreich ataxia. PLoS One 8: e54791, 2013.
5. Bandiera S, Matégot R, Girard M, Demongeot J, and Henrion-Caude A. MitomiRs delineating the intracellular localization of microRNAs at mitochondria. Free Radic Biol Med 64: 12-19, 2013.
6. Bánfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, and Krause KH. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 279: 46065-46072, 2004.
7. Bedard K and Krause KH. The NOX family of ROSgenerating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007.
8. Berndt JD, Moon RT, and Major MB. Beta-catenin gets jaded and von Hippel-Lindau is to blame. Trends Biochem Sci 34: 101-104, 2009.
9. Bienertova-Vasku J, Sana J, and Slaby O. The role of microRNAs in mitochondria in cancer. Cancer Lett 336: 1-7, 2013.
10. Block K. Emerging Research and Treatments in Renal Cell Carcinoma. Rijeka, Croatia: In Tech, 2012, p. 137.
11. Block K and Gorin Y. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat Rev Cancer 12: 627-637, 2012.
12. Block K, Gorin Y, and Abboud HE. Subcellular localization of NOX4 and regulation in diabetes. Proc Natl Acad Sci U S A 106: 14385-14390, 2009.
13. Block K, Gorin Y, Hoover P, Williams P, Chelmicki T, Clark RA, Yoneda T, and Abboud HE. NAD(P)H oxidases regulate HIF-2alpha protein expression. J Biol Chem 282: 8019-8026, 2007.
14. Block K, Gorin Y, New DD, Eid A, Chelmicki T, Reed A, Choudhury GG, Parekh DJ, and Abboud HE. The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol 176: 2447-2455, 2010.
15. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, Croce CM, Weinstein JN, and Sadee W. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6: 1483-1491, 2007.
16. Bonner MY and Arbiser JL. The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem 6: 1413-1422, 2014.
17. Boström AK, Lindgren D, Johansson ME, and Axelson H. Effects of TGF-b signaling in clear cell renal cell carcinoma cells. Biochem Biophys Res Commun 435: 126-133, 2013.
18. Boudreau HE, Casterline BW, Rada B, Korzeniowska A, and Leto TL. Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med 53: 1489-1499, 2012.
19. Brewer AC, Murray TV, Arno M, Zhang M, Anilkumar NP, Mann GE, and Shah AM. Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med 51: 205-215, 2011.
20. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1: 409-414, 2005.
21. Bussolati B, Bruno S, Grange C, Ferrando U, and Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 22: 3696-3705, 2008.
22. Cadenas E and Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 29: 222-230, 2000.
23. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49, 2013.
24. Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA 308: 581-590, 2012.
25. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, and Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59: 671-681, 2011.
26. 2 sensing. J Biol Chem 275: 25130-25138, 2000.
27. Chandel NS, Vander Heiden MG, Thompson CB, and Schumacker PT. Redox regulation of p53 during hypoxia. Oncogene 19: 3840-3848, 2000.
28. Chen J, Zhang D, Zhang W, Tang Y, Yan W, Guo L, and Shen B. Clear cell renal cell carcinoma associated microRNA expression signatures identified by an integrated bioinformatics analysis. J Transl Med 11: 169, 2013.
29. Cheng G, Cao Z, Xu X, van Meir EG, and Lambeth JD. Homologs of gp91phox: cloning and tissue expression of NOX3, NOX4, and NOX5. Gene 269: 131-140, 2001.
30. Cheng G and Lambeth JD. NOXO1, regulation of lipid binding, localization, and activation of NOX1 by the Phox homology (PX) domain. J Biol Chem279: 4737-4742, 2004.
31. Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, Bharti A, Seldin DC, Lecker SH, Dominguez I, and Cohen HT. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 10: 1208-1216, 2008.
32. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, and Yousef GM. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 183: 743-751, 2010.
33. Christensen EI, Birn H, Rippe B, and Maunsbach AB. Controversies in nephrology: renal albumin handling, facts, and artifacts! Kidney Int 72: 1192-1194, 2007.
34. Clavijo-Cornejo D, Enriquez-Cortina C, López-Reyes A, Domínguez-Pérez M, Nuño N, Domínguez-Meraz M, Bucio L, Souza V, Factor VM, Thorgeirsson SS, Gutiérrez-Ruiz MC, and Gómez-Quiroz LE. Biphasic regulation of the NADPH oxidase by HGF/c-Met signaling pathway in primary mouse hepatocytes. Biochimie 95: 1177-1184, 2013.
35. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, and Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900-907, 2005.
36. Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA; Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, and Creighton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26: 319-330, 2014.
37. Dey N, Das F, Ghosh-Choudhury N, Mandal CC, Parekh DJ, Block K, Kasinath BS, Abboud HE, and Choudhury GG. microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One 7: e37366, 2012.
38. Diebold I, Petry A, Hess J, and Görlach A. The NADPH oxidase subunit NOX4 is a new target gene of the hypoxia-inducible factor-1. Mol Biol Cell 21: 2087-2096, 2010.
39. Drabkin HA and Gemmill RM. Cholesterol and the development of clear-cell renal carcinoma. Curr Opin Pharmacol 12: 742-750, 2012.
40. Duarte FV, Palmeira CM, and Rolo AP. The Role of microRNAs in mitochondria: small players acting wide. Genes 5: 865-886, 2014.
41. Dupuy C, Ohayon R, Valent A, Noël-Hudson MS, Dème D, and Virion A. Purification of a novel flavoprotein involved in the thyroid NADPH oxidase. Cloning of the porcine and human cdnas. J Biol Chem 274: 37265-37269, 1999.
42. Ellis L, Atadja PW, and Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8: 1409-1420, 2009.
43. Féraille E, Dizin E, Roth I, Derouette JP, Szanto I, Martin PY, de Seigneux S, and Hasler U. NADPH oxidase 4 deficiency reduces aquaporin-2 mRNA expression in cultured renal collecting duct principal cells via increased PDE3 and PDE4 activity. PLoS One 9: e87239, 2014.
44. Fitzgerald JP, Nayak B, Shanmugasundaram K, Friedrichs W, Sudarshan S, Eid AA, DeNapoli T, Parekh DJ, Gorin Y, and Block K. NOX4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6-and 8-production. PLoS One 7: e30712, 2012.
45. Fu Y, Zhang Y, Wang Z, Wang L, Wei X, Zhang B, Wen Z, Fang H, Pang Q, and Yi F. Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol 32: 581-589, 2010.
46. Galleggiante V, Rutigliano M, Sallustio F, Ribatti D, Ditonno P, Bettocchi C, Selvaggi FP, Lucarelli G, and Battaglia M. CTR2 identifies a population of cancer cells with stem cell-like features in patients with clear cell renal cell carcinoma. J Urol 192: 1831-1841, 2014.
47. Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, Evans C, and Weiss RH. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer 130: 2791-2800, 2012.
48. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Rüegg C, Krause KH, and Imhof BA. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARa mediated mechanism. PLoS One 6: e14665, 2011.
49. Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res 1: 289-299, 2006.
50. Geiszt M, Kopp JB, Várnai P, and Leto TL. Identification of reNOX, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 97: 8010-8014, 2000.
51. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, and Linehan WM. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90, 1994.
52. Gooch JL, Tang Y, Ricono JM, and Abboud HE. Insulinlike growth factor-I induces renal cell hypertrophy via a calcineurin-dependent mechanism. J Biol Chem276: 42492-42500, 2001.
53. Gordillo GM, Biswas A, Khanna S, Pan X, Sinha M, Roy S, and Sen CK. Dicer knockdown inhibits endothelial cell tumor growth via microRNA 21a-3p targeting of NOX-4. J Biol Chem 289: 9027-9038, 2014.
54. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, and Abboud HE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280: 39616-39626, 2005.
55. Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, and Cairns P. Micro-RNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15: 329-341, 2014.
56. Goyal P, Weissmann N, Grimminger F, Hegel C, Bader L, Rose F, Fink L, Ghofrani HA, Schermuly RT, Schmidt HH, Seeger W, and Hänze J. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med 36: 1279-1288, 2004.
57. Grange C, Collino F, Tapparo M, and Camussi G. Oncogenic micro-RNAs and renal cell carcinoma. Front Oncol 4: 49, 2014.
58. Gregg JL, Turner RM 2nd, Chang G, Joshi D, Zhan Y, Chen L, and Maranchie JK. NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2a. Cancer Res 74: 3501-3511, 2014.
59. Guan Y and Breyer MD. Peroxisome proliferatoractivated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 60: 14-30, 2001.
60. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT. Mitochondrial complex III is required for hypoxiainduced ROS production and cellular oxygen sensing. Cell Metab 1: 401-408, 2005.
61. Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, Mikklineni N, Fiegoli B, Kim PH, Voss MH, Shen H, Laird PW, Sander C, Reuter VE, Motzer RJ, Hsieh JJ, and Russo P. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 105: 1862-1870, 2013.
62. Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, Reuter VE, Cheng EH, Sander C, and Hsieh JJ. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29: 104-116, 2016.
63. Hale LJ and Coward RJ. Insulin signalling to the kidney in health and disease. Clin Sci (Lond). 124: 351-370, 2013.
64. Halliwell B, Zhao K, and Whiteman M. Nitric oxide and peroxynitrite. The ugly, the uglier and the not so good: a personal view of recent controversies. Free Radic Res 31: 651-669, 1999.
65. Harb-de la Rosa A, Acker M, Kumar RA, and Manoharan M. Epigenetics application in the diagnosis and treatment of bladder cancer. Can J Urol 22: 7947-7951, 2015.
66. Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, Gajda MR, and Junker K. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29: 367-373, 2011.
67. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, and Baylin S. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91: 9700-9704, 1994.
68. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, and Brooks JD. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162: 925-932, 2003.
69. Hiraga R, Kato M, Miyagawa S, and Kamata T. Nox4-derived ROS signaling contributes to TGF-b-induced epithelial-mesenchymal transition in pancreatic cancer cells. Anticancer Res 33: 4431-4438, 2013.
70. Hitchler MJ and Domann FE. Redox regulation of the epigenetic landscape in cancer: a role for metabolic reprogramming in remodeling the epigenome. Free Radic Biol Med 53: 2178-2187, 2012.
71. Hodgkinson CP, Kang MH, Dal-Pra S, Mirotsou M, and Dzau VJ. MicroRNAs and cardiac regeneration. Circ Res 116: 1700-1171, 2015.
72. Hu CJ, Wang LY, Chodosh LA, Keith B, and Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374, 2003.
73. Hu T, Ramachandrarao SP, Siva S, Valancius C, Zhu Y, Mahadev K, Toh I, and Goldstein BJ, Woolkalis M, and Sharma K. Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am J Physiol Renal Physiol 289: F816-F825, 2005.
74. Huang J, Yao X, Zhang J, Dong B, Chen Q, Xue W, Liu D, and Huang Y. Hypoxia-induced downregulation of miR-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma. Cancer Sci 104: 1609-1617, 2013.
75. Isaacs WB, Lerman MI, Zbar B, and Linehan WM. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90, 1994.
76. Kalantar-Zadeh K, Streja E, Kovesdy CP, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 85: 991-1001, 2010.
77. Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, Majid S, Tanaka Y, Kawamoto K, Enokida H, Nakagawa M, and Dahiya R. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 69: 8603-8610, 2009.
78. Khan MI, Czarnecka AM, Helbrecht I, Bartnik E, Lian F, and Szczylik C. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. Stem Cell Res Ther 6: 178, 2015, 2015.
79. Kim K, Taylor SL, Ganti S, Guo L, Osier MV, and Weiss RH. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 15: 293-303, 2011.
80. Kim WJ, Gersey Z, and Daaka Y. Rap1GAP regulates renal cell carcinoma invasion. Cancer Lett 320: 65-71, 2012.
81. Kim Y and Kim VN. MicroRNA factory: RISC assembly from precursor microRNAs. Mol Cell 46: 384-386, 2012.
82. Kluzek S, Newton JL, and Arden NK. Osteoarthritis a metabolic disorder? Br Med Bull 115: 111-121, 2015.
83. Kondo K, Klco J, Nakamura E, Lechpammer M, and Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246, 2002.
84. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, and Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23: 1949-1956, 2004.
85. Kurban G, Hudon V, Duplan E, Ohh M, and Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 66: 1313-1319, 2006.
86. Lambeth JD. NOX enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 43: 332-347, 2007.
87. Lassègue B and Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30: 653-661, 2010.
88. Li J and Lam M. Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Reproducibility project: Cancer biology. Elife 4: e06434, 2015.
89. Li J, Wang E, Dutta S, Lau JS, Jiang SW, Datta K, and Mukhopadhyay D. Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux. Mol Cell Biol 27: 7345-7353, 2007.
90. Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, Chen Z, and Zhao J. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res 21: 83-91, 2013.
91. Liu Q, Jin J, Ying J, Sun M, Cui Y, Zhang L, Xu B, Fan Y, and Zhang Q. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma. Int J Mol Sci 16: 10636-10649, 2015.
92. Lustgarten MS, Bhattacharya A, Muller FL, Jang YC, Shimizu T, Shirasawa T, Richardson A, and Van Remmen H. Complex I generated, mitochondrial matrix-directed superoxide is released from the mitochondria through voltage dependent anion channels. Biochem Biophys Res Commun 422: 515-521, 2012.
93. Lv L, Huang F, Mao H, Li M, Li X, Yang M, and Yu X. MicroRNA-21 is overexpressed in renal cell carcinoma. Int J Biol Markers 28: 201-207, 2013.
94. Ma J, Dong C, and Ji C. MicroRNA and drug resistance. Cancer Gene Ther 17: 523-531, 2010.
95. Magenta A, Greco S, Gaetano C, and Martelli F. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci 14: 17319-17346, 2013.
96. Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, and Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 9: 32-43, 2015.
97. Mariappan MM, Feliers D, Mummidi S, Choudhury GG, and Kasinath BS. High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes 56: 476-485, 2007.
98. Marin T, Gongol B, Chen Z, Woo B, Subramaniam S, Chien S, and Shyy JY. Mechanosensitive microRNAs-role in endothelial responses to shear stress and redox state. Free Radic Biol Med 64: 61-68, 2013.
99. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, and Ratcliffe PJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 94: 8104-8109, 1997.
100. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kögler C, Ratschek M, Schmeller N, Sperl W, and Kofler B. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res 14: 2270-2275, 2008.
101. Meng H, Chen G, Gao HM, Song X, Shi Y, and Cao L. The emerging nexus of active DNA demethylation and mitochondrial oxidative metabolism in post-mitotic neurons. Int J Mol Sci 15: 22604-22625, 2014.
102. Mittal M, Roth M, König P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, Kummer W, Klepetko W, Hoda MA, Fink L, Hänze J, Seeger W, Grimminger F, Schmidt HH, and Weissmann N. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 101: 258-267, 2007.
103. Moestrup SK and Nielsen LB. The role of the kidney in lipid metabolism. Curr Opin Lipidol 16: 301-306, 2005.
104. Moreno SM, Benítez IA, and Martínez González MA. Ultrastructural studies in a series of 18 cases of chromophobe renal cell carcinoma. Ultrastruct Pathol 29: 377-387, 2005.
105. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, and Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29: 2104-2117, 2010.
106. Muller FL, Liu Y, and Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 279: 49064-49073, 2004.
107. Müller S and Nowak K. Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. Biomed Res Int 948408, 2014.
108. Munari E, Marchionni L, Chitre A, Hayashi M, Martignoni G, Brunelli M, Gobbo S, Argani P, Allaf M, Hoque MO, and Netto GJ. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol 45: 1130-1138, 2014.
109. Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, Courtneidge SA, Knaus UG, Brat DJ, Arbiser JL, and Bellamkonda RV. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med 4: 127ra36, 2012.
110. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H, Seto M, and Moriyama M. Genomewide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 216: 418-427, 2008.
111. Nayak BK, Feliers D, Sudarshan S, Friedrichs WE, Day RT, New DD, Fitzgerald JP, Eid A, Denapoli T, Parekh DJ, Gorin Y, and Block K. Stabilization of HIF-2a through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene 32: 3147-3155, 2013.
112. New DD, Block K, Bhandhari B, Gorin Y, and Abboud HE. GF-I increases the expression of fibronectin by NOX4-dependent Akt phosphorylation in renal tubular epithelial cells. Am J Physiol Cell Physiol 302: C122-C130, 2012.
113. Nielsen SF, Nordestgaard BG, and Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 367: 1792-802, 2012.
114. Ning B, Li W, Zhao W, and Wang R. Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin 48: 97-109, 2015.
115. Oshimori N, Oristian D, and Fuchs E. TGF-b promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160: 963-976, 2015.
116. Panchenko MV, Zhou MI, and Cohen HT. von Hippel-Lindau partner Jade-1 is a transcriptional co-activator associated with histone acetyltransferase activity. J Biol Chem 279: 56032-56041, 2004.
117. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, and Teh BT. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 35: 109-114, 2009.
118. Pfaffenroth EC and Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther 8: 779-790, 2008.
119. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, and Tomlinson IP. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14: 2231-2239, 2005.
120. Pothiwala P, Jain SK, and Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord 7: 279-288, 2009.
121. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, and Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 31: 29-59, 2010.
122. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Saavedra E, and Moreno-Sánchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med 31: 145-170, 2010.
123. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, and Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686, 2005.
124. Redova M, Svoboda M, and Slaby O. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun 405: 153-156, 2011.
125. Ricketts CJ, Hill VK, and Linehan WM. Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One 9: e85621, 2014.
126. Rönn T and Ling C. DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes. Epigenomics 7: 451-460, 2015.
127. Russo I, Cosentino C, Del Giudice E, Broccoletti T, Amorosi S, Cirillo E, Aloj G, Fusco A, Costanzo V, and Pignata C. In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol 16: 755-759, 2009.
128. Rzem R, Veiga-da-Cunha M, Noël G, Goffette S, Nassogne MC, Tabarki B, Schö ller C, Marquardt T, Vikkula M, and Van Schaftingen E. A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci U S A 101: 16849-16854, 2004.
129. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, and Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45: 860-867, 2013.
130. Selemidis S, Sobey CG, Wingler K, Schmidt HH, and Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120: 254-291, 2008.
131. Sertznig P, Seifert M, Tilgen W, and Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212: 1-12, 2007.
132. Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, and Verma A. Role of DNA methylation in renal cell carcinoma. Hematol Oncol 8: 88, 2015.
133. Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, Kho EY, Ghosh AP, Kirkman R, Velu S, Dutta S, Chenna B, Rea SL, Mishur RJ, Li Q, Johnson-Pais TL, Guo L, Bae S, Wei S, Block K, and Sudarshan S. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov 4: 1290-1298, 2014.
134. Shiose A, Kuroda J, Tsuruya K, Hirai M, Hirakata H, Naito S, Hattori M, Sakaki Y, and Sumimoto H. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 276: 1417-1423, 2001.
135. Solaini G, Baracca A, Lenaz G, and Sgarbi G. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta 1797: 1171-1177, 2010.
136. Solarek W, Czarnecka AM, Escudier B, Bielecka ZF, Lian F, and Szczylik C. Insulin and IGFs in renal cancer risk and progression. Endocr Relat Cancer 22: R253-R264, 2015.
137. Spector Y, Fridman E, Rosenwald S, Zilber S, Huang Y, Barshack I, Zion O, Mitchell H, Sanden M, and Meiri E. Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas. Mol Oncol 7: 732-738, 2013.
138. Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, Galindo C, Mollapour M, Scroggins B, Goode N, Lee MJ, Gourlay CW, Trepel J, Linehan WM, and Neckers L. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxiainducible transcription factor 1alpha stabilization by glucosedependent generation of reactive oxygen species. Mol Cell Biol 29: 4080-4090, 2009.
139. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, and Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox1. Nature 401: 79-82, 1999.
140. Sun XZ, Vinci C, Makmura L, Han S, Tran D, Nguyen J, Hamann M, Grazziani S, Sheppard S, Gutova M, Zhou F, Thomas J, and Momand J. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid Redox Signal 5: 655-665, 2003.
141. Tachibana K, Yamasaki D, Ishimoto K, and Doi T. The role of PPARs in cancer. PPAR Res 2008: 102737, 2008.
142. Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M, Fini M, and Russo MA. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxid Med Cell Longev 2016: 3907147, 2016.
143. Takahashi M, Papavero V, Yuhas J, Kort E, Kanayama HO, Kagawa S, Baxter RC, Yang XJ, Gray SG, and Teh BT. Altered expression of members of the IGF-axis in clear cell renal cell Int. carcinoma. J Oncol 26: 923-931, 2005.
144. Takamura T, Misu H, Matsuzawa-Nagata N, Sakurai M, Ota T, Shimizu A, Kurita S, Takeshita Y, Ando H, Honda M, and Kaneko S. Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients. Obesity 16: 2601-2609, 2008.
145. Tickoo SK, Lee MW, Eble JN, Amin M, Christopherson T, Zarbo RJ, and Amin MB. Ultrastructural observations on mitochondria and microvesicles in renal oncocytoma, chromophobe renal cell carcinoma, and eosinophilic variant of conventional (clear cell) renal cell carcinoma. Am J Surg Pathol 24: 1247-1256, 2000.
146. Tomasetti M, Santarelli L, Neuzil J, and Dong L. MicroRNA regulation of cancer metabolism: role in tumour suppression. Mitochondrion 19: 29-38, 2014.
147. Trionfini P, Benigni A, and Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 11: 23-33, 2015.
148. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, and Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815, 1999.
149. Velu CS, Niture SK, Doneanu CE, Pattabiraman N, and Srivenugopal KS. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNAbinding domain during oxidative stress. Biochemistry 46: 7765-7780, 2007.
150. Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 70: 363-374, 2005.
151. Wang HJ, Huang YL, Shih YY, Wu HY, Peng CT, and Lo WY. MicroRNA-146a decreases high glucose/thrombininduced endothelial inflammation by inhibiting NAPDH oxidase 4 expression. Mediators Inflamm 379537, 2014.
152. WARBURG O. On respiratory impairment in cancer cells. Science 124: 269-270, 1956.
153. WARBURG O. On the origin of cancer cells. Science 123: 309-314, 1956.
154. Wendt MK, Tian M, and Schiemann WP. Deconstructing the mechanisms and consequences of TGF-b-induced EMT during cancer progression. Cell Tissue Res 347: 85-101, 2012.
155. White NM and Yousef GM. MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. BMC Med 8: 65, 2010.
156. Wotschofsky Z, Meyer HA, Jung M, Fendler A, Wagner I, Stephan C, Busch J, Erbersdobler A, Disch AC, Mollenkopf HJ, and Jung K. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem 417: 233-241, 2011.
157. Yan Q, Bartz S, Mao M, Li L, and Kaelin WG, Jr. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol 27: 2092-2102, 2007.
158. Yan S, Liu G, Pei C, Chen W, Li P, Wang Q, Jin X, Zhu J, Wang M, and Liu X. Inhibition of NADPH oxidase protects against metastasis of human lung cancer by decreasing microRNA-21. Anticancer Drugs 26: 388-398, 2015.
159. Yang L, Yuan J, Liu L, Shi C, Wang L, Tian F, Liu F, Wang H, Shao C, Zhang Q, Chen Z, Qin W, and Wen W. a-linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-c activation and COX-2 inhibition. Oncol Lett 6: 197-202, 2013.
160. Yang W, Yoshigoe K, Qin X, Liu JS, Yang JY, Niemierko A, Deng Y, Liu Y, Dunker A, Chen Z, Wang L, Xu D, Arabnia HR, Tong W, and Yang M. Identification of genes and pathways involved in kidney renal clear cell carcinoma. BMC Bioinformatics 17: S2, 2014.
161. Yang WH, Su YH, Hsu WH, Wang CC, Arbiser JL, and Yang MH. Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation. Oncogene 35: 2287-2298, 2016.
162. Youssef YM, White NM, Grigull J, Krizova A, and Samy C, Mejia-Guerrero S, Evans A, and Yousef GM. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59: 721-730, 2011.
163. Yue D, Zhang Z, Li J, Chen X, Ping Y, Liu S, Shi X, Li L, Wang L, Huang L, Zhang B, Sun Y, and Zhang Y. Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer. Exp Cell Res 336: 141-149, 2015.
164. Zhang B, Liu Z, and Hu X. Inhibiting cancer metastasis via targeting NAPDH oxidase 4. Biochem Pharmacol 86: 253-266, 2013.
165. Zhang L, Xul B, Chen S, Lu K, Liu C, Wang Y, Zhao Y, Zhang X, Liu D, and Chen M. The complex roles of microRNAs in the metastasis of renal cell carcinoma. J Nanosci Nanotechnol 13: 3195-3203, 2013.
166. Zhang T, Niu X, Liao L, Cho EA, and Yang H. The contributions of HIF-target genes to tumor growth in RCC. PLoS One 8: e80544, 2013.
167. Zimmer M, Doucette D, Siddiqui N, and Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/-tumors. Mol Cancer Res 2: 89-95, 2004.